T-Cell Specific Surface Glycoprotein CD28 Market
T-Cell Specific Surface Glycoprotein CD28 Market Size, Share and Trends Analysis Report, By Type (FPT-155, FR-104, Lulizumab Pegol, and Others), By Application (Plaque Psoriasis, Solid Tumor, Cancer, Acute Renal Failure (ARF), and Others), Forecast Period, (2026-2035)
Industry Overview
T-cell specific surface glycoprotein CD28 market was valued at $XX million in 2025 and is projected to reach $XX million by 2035, growing at a CAGR of X.X% during the forecast period (2026-2035). The global T-cell-specific surface glycoprotein CD28 market is expanding as immunological research increasingly emphasizes precise T-cell costimulatory pathways. Growing demand for validated molecular targets in immune response modulation has strengthened the relevance of CD28-focused products. Regulatory emphasis on mechanism-driven therapeutic development has further encouraged consistent utilization of CD28-related tools. In addition, sustained funding for immune profiling studies has supported continuous procurement of specialized reagents. The market also benefits from long-term research programs requiring standardized immune markers. Collectively, these factors are contributing to steady and measurable market growth.
Market Dynamics
Expansion of Immuno-Oncology and Translational Research Applications
The global T-cell-specific surface glycoprotein CD28 market is witnessing steady growth driven by increasing utilization of CD28-related reagents and assays in immuno-oncology and translational research. Pharmaceutical and biotechnology companies are intensifying investments in T-cell activation and co-stimulatory pathway studies to support novel therapeutic development. Rising clinical research activity in solid tumors and immune-mediated disorders is expanding demand for CD28-specific analytical tools. In parallel, academic and contract research organizations are adopting standardized CD28 assays to improve reproducibility in immune response evaluation. The growing emphasis on mechanism-based drug discovery further reinforces sustained product demand. Overall, research-led consumption continues to anchor market stability.
Gradual Shift Toward Advanced and High-Specificity CD28 Products
A key trend shaping the Global T-Cell Specific Surface Glycoprotein CD28 Market is the transition toward high-specificity, application-optimized reagents and diagnostic solutions. Manufacturers are focusing on improving sensitivity, consistency, and validation standards to meet regulatory and end-user expectations. Increasing adoption of advanced flow cytometry, multiplex assays, and precision immunology platforms is influencing product innovation. End users are favoring premium, well-characterized CD28 products that reduce experimental variability and shorten development timelines. This shift supports higher average selling prices and strengthens supplier differentiation. As a result, value-driven product development is becoming a central competitive strategy.
Market Segmentation
- Based on the type, the market is segmented into FPT-155, FR-104, lulizumab pegol, and others.
- Based on the application, the market is segmented into plaque psoriasis, solid tumor, cancer, acute renal failure (ARF), and others.
FPT-155 Segment to Lead the Market with the Largest Share
The global T-cell specific surface glycoprotein CD28 Market is demonstrating growth influenced by the increasing research focus on FPT-155 as a selective modulator of immune costimulatory pathways. Ongoing preclinical and clinical evaluations of FPT-155 have intensified demand for CD28-related analytical and validation products. Research institutions and biopharmaceutical developers are expanding experimental programs to better understand their mechanistic profile. This has resulted in consistent utilization of CD28-specific assays and reagents. The need for accurate immune response measurement further supports market activity.
Solid Tumor: A Key Segment in Market Growth
Growth in the Global T-cell-specific surface glycoprotein CD28 market is supported by rising investigative efforts in solid tumor research. CD28-related pathways are increasingly examined for their role in tumor immune response and resistance mechanisms. This has led to higher adoption of CD28 markers in oncology-focused studies. Research programs aimed at improving immunotherapeutic outcomes rely on precise immune signaling analysis. As solid tumor pipelines expand, demand for validated CD28 products continues to rise. These developments are strengthening the market’s growth trajectory.
Regional Outlook
The global T-cell specific surface glycoprotein CD28 market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Growing Research Infrastructure in Asia-Pacific
The Asia-Pacific T-cell specific surface glycoprotein CD28 Market is growing as research infrastructure and clinical capabilities continue to strengthen across the region. Increasing participation in global clinical studies has expanded the use of standardized immunological tools. Investment in biotechnology and life sciences is supporting broader adoption of CD28-related products. Regional institutions are focusing on improving immune research quality and output. Cost-effective manufacturing and expanding laboratory networks enhance accessibility. These combined factors are driving sustained growth in the Asia-Pacific market.
North America Region Dominates the Market with Major Share
The North America T-cell-specific surface glycoprotein CD28 market is expanding due to a strong concentration of advanced immunology research and drug development activities. The region hosts a large number of clinical research programs investigating T-cell modulation strategies. Consistent funding availability supports sustained procurement of CD28-related products. Collaboration between academic centers and biopharmaceutical companies further accelerates product adoption. High regulatory standards also encourage the use of well-validated immune markers. Together, these factors contribute to steady regional market growth.
Market Players Outlook
The major companies operating in the global T-cell-specific surface glycoprotein CD28 market include Abcam Ltd., Becton, Dickinson & Company (BD Biosciences), Bio?Techne Corp., Miltenyi Biotec B.V. & Co. KG, and Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In April 2024, AbCellera announced new data on its T-cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 at the San Diego Convention Center, with three posters being presented on April 8 and one on April 9. Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space. Costimulatory CD28-binding antibodies that stimulate T cells without superagonist activity.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global T-cell-specific surface glycoprotein CD28 market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global T-Cell Specific Surface Glycoprotein CD28 Market Sales Analysis – Type | Application ($ Million)
- T-Cell Specific Surface Glycoprotein CD28 Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key T-Cell Specific Surface Glycoprotein CD28 Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the T-Cell Specific Surface Glycoprotein CD28 Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global T-Cell Specific Surface Glycoprotein CD28 Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global T-Cell Specific Surface Glycoprotein CD28 Market: Impact Analysis
- Market Opportunities
- Opportunities For Global T-Cell Specific Surface Glycoprotein CD28 Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – T-Cell Specific Surface Glycoprotein CD28 Market Revenue and Share by Manufacturers
- T-Cell Specific Surface Glycoprotein CD28 Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Abcam Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Becton, Dickinson & Company (BD Biosciences)
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Bio?Techne Corp.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Miltenyi Biotec B.V. & Co. KG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Thermo Fisher Scientific Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Abcam Ltd.
- Key Company Analysis
- Global T-Cell Specific Surface Glycoprotein CD28 Market Sales Analysis by Type ($ Million)
- FPT-155
- FR-104
- Lulizumab Pegol
- Others
- Global T-Cell Specific Surface Glycoprotein CD28 Market Sales Analysis by Application ($ Million)
- Plaque Psoriasis
- Solid Tumor
- Cancer
- Acute Renal Failure (ARF)
- Others
- Regional Analysis
- North American T-Cell Specific Surface Glycoprotein CD28 Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European T-Cell Specific Surface Glycoprotein CD28 Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific T-Cell Specific Surface Glycoprotein CD28 Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World T-Cell Specific Surface Glycoprotein CD28 Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Abbexa Ltd
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abcam Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aladdin Scientific
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aviva Systems Biology
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Becton, Dickinson & Company (BD Biosciences)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BioLegend (Revvity)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bioss Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bio?Techne Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Boster Biological Technology Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BPS Bioscience, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GeneTex, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GenScript Biotech Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Leinco Technologies Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Mabtech AB
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Miltenyi Biotec B.V. & Co. KG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novus Biologicals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- R&D Systems
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sino Biological Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Thermo Fisher Scientific Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Wuhan Fine Biotech Co., Ltd. (FineTest)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbexa Ltd
1. Global T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Type, 2025–2035 ($ Million)
2. Global FPT-155 T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global FR-104 T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Lulizumab Pegol T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Other T-Cell Specific Surface Glycoprotein CD28 Type Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Application, 2025–2035 ($ Million)
7. Global T-Cell Specific Surface Glycoprotein CD28 For Plaque Psoriasis Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global T-Cell Specific Surface Glycoprotein CD28 For Solid Tumor Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global T-Cell Specific Surface Glycoprotein CD28 For Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global T-Cell Specific Surface Glycoprotein CD28 For Acute Renal Failure (ARF) Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global T-Cell Specific Surface Glycoprotein CD28 For Other Application Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Region, 2025–2035 ($ Million)
13. North American T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Region, 2025–2035 ($ Million)
14. North American T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Type, 2025–2035 ($ Million)
15. North American T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Application, 2025–2035 ($ Million)
16. European T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Region, 2025–2035 ($ Million)
17. European T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Type, 2025–2035 ($ Million)
18. European T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Application, 2025–2035 ($ Million)
19. Asia-Pacific T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Region, 2025–2035 ($ Million)
20. Asia-Pacific T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Type, 2025–2035 ($ Million)
21. Asia-Pacific T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Application, 2025–2035 ($ Million)
22. Rest of the World T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Region, 2025–2035 ($ Million)
23. Rest of the World T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Type, 2025–2035 ($ Million)
24. Rest of the World T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Application, 2025–2035 ($ Million)
1. Global T-Cell Specific Surface Glycoprotein CD28 Market Share by Type, 2025 Vs 2035 (%)
2. Global FPT-155 T-Cell Specific Surface Glycoprotein CD28 Market Share by Region, 2025 Vs 2035 (%)
3. Global FR-104 T-Cell Specific Surface Glycoprotein CD28 Market Share by Region, 2025 Vs 2035 (%)
4. Global Lulizumab Pegol T-Cell Specific Surface Glycoprotein CD28 Market Share by Region, 2025 Vs 2035 (%)
5. Global Other T-Cell Specific Surface Glycoprotein CD28 Type Market Share by Region, 2025 Vs 2035 (%)
6. Global T-Cell Specific Surface Glycoprotein CD28 Market Share by Application, 2025 Vs 2035 (%)
7. Global T-Cell Specific Surface Glycoprotein CD28 For Plaque Psoriasis Market Share by Region, 2025 Vs 2035 (%)
8. Global T-Cell Specific Surface Glycoprotein CD28 For Solid Tumor Market Share by Region, 2025 Vs 2035 (%)
9. Global T-Cell Specific Surface Glycoprotein CD28 For Cancer Market Share by Region, 2025 Vs 2035 (%)
10. Global T-Cell Specific Surface Glycoprotein CD28 For Acute Renal Failure (ARF) Market Share by Region, 2025 Vs 2035 (%)
11. Global T-Cell Specific Surface Glycoprotein CD28 For Other Application Market Share by Region, 2025 Vs 2035 (%)
12. Global T-Cell Specific Surface Glycoprotein CD28 Market Research and Analysis by Region, 2025–2035 ($ Million)
13. US T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
14. Canada T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
15. UK T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
16. France T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
17. Germany T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
18. Italy T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
19. Spain T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
20. Russia T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
21. Rest of Europe T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
22. India T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
23. China T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
24. Japan T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
25. South Korea T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
26. Australia and New Zealand T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
27. ASEAN Economies T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
28. Rest of Asia-Pacific T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
29. Latin America T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
30. Middle East and Africa T-Cell Specific Surface Glycoprotein CD28 Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the T-Cell Specific Surface Glycoprotein CD28 Market in 2025 is estimated to be around $XX million.
North America holds the largest share in the T-Cell Specific Surface Glycoprotein CD28 Market.
Leading players in the T-Cell Specific Surface Glycoprotein CD28 Market include Abcam Ltd., Becton, Dickinson & Company (BD Biosciences), Bio?Techne Corp., Miltenyi Biotec B.V. & Co. KG, and Thermo Fisher Scientific Inc., among others.
The T-Cell Specific Surface Glycoprotein CD28 Market is expected to grow at a CAGR of X.X% from 2026 to 2035.
The T-Cell Specific Surface Glycoprotein CD28 Market growth is driven by increasing research in immuno-oncology and rising development of targeted immune-modulating therapies.
